Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Axitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 3/20 | 1.00 |
| ▸ | FLT4 known ✓ | P35916 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 7/20 | 1.00 |
| ▸ | LCK | P06239 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | CSF1R | P07333 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | KIT | P10721 | 2/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 2/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 2/20 | 1.00 |
| ▸ | TYK2 | P29597 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Axitinib SCHEMBL29384419 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL843204 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL2826667 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29387511 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL172918 | 1.00 | KDR (1.00) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248175 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL5248178 | 0.99 | KDR (0.98) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL23044964 | 0.94 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| Axitinib SCHEMBL29459456 | 0.94 | KDR (0.88) | KDRFGFR1FLT1FLT4LCK | |
| SCHEMBL24503457 | 0.91 | KDR (0.84) | KDRFGFR1FLT1FLT4LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16489 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144866-A1 | METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075735-A | Therapeutic combinations comprising anti-FOLR 1 immunoconjugates | — | 2026-05-26 | — | — | CN | claimed |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | claimed |
| US-20260142007-A1 | DIGITAL THERAPEUTICS AND COMBINATION THERAPY FOR THE TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR (TGCT) | REMEPY HEALTH LTD (IL) | 2026-05-21 | — | — | US | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107180-A1 | IMPLANT INJECTOR DEVICE | OCULAR THERAPEUTIX, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113993592-A | Compounds against cancers bearing tyrosine kinase inhibitor resistant EGFR mutations | 得克萨斯大学体系董事会 | 2022-01-28 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20220028512-A1 | SMART DOSING FOR CANCER THERAPY | OptimDosing, LLC | 2022-01-27 | — | — | US | claimed |
| US-20220024777-A1 | NOVEL AMORPHOUS ACTIVE PHARMACEUTICAL INGREDIENTS COMPRISING SUBSTANTIALLY AMORPHOUS MESOPOROUS MAGNESIUM CARBONATE | DISRUPTIVE PHARMA AB (SE) | 2022-01-27 | — | — | US | claimed |
| US-20220023213-A1 | NANOCRYSTALLINE EYE DROP, PREPARATION METHOD AND USE THEREOF | CHENGDU RUIMU PHARMACEUTICALS CO., LTD. (CN) | 2022-01-27 | — | — | US | claimed |
| WO-2022019828-A1 | TARGETING IMMUNE PATHOLOGIES INDUCED BY HIGHLY PATHOGENIC CORONAVIRUSES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-01-27 | — | — | WO | claimed |
| WO-2022020720-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| CN-113967261-A | Application of FOLR1 inhibitor and medicine mixture for treating liver cancer | 中国科学院大连化学物理研究所 | 2022-01-25 | — | — | CN | claimed |